Overview
Bloomlife provides a remote prenatal care platform for healthcare providers, anchored by the FDA-cleared MFM-Pro wearable patch that non-invasively monitors maternal and fetal heart rates outside the clinic. The system replaces manual, in-clinic monitoring by delivering continuous remote data that integrates with EMR workflows and supports third-party devices, while clinical teams interpret the data and Bloomlife handles logistics. Revenue comes from shared reimbursement with insurers for remote patient monitoring within a B2B2C model focused on high-risk pregnancies and maternal health. The goal is to make prenatal care safer and more accessible by reducing unnecessary clinic visits and improving management of maternal and fetal health.
Work here?Claim your company
Simplify's take
What believers are saying
- Bloomlife raised $4.5 million in March 2025, extending commercialization runway.
- Its 2026 website claims doubled compliance and reduced poorly controlled blood pressure.
- Holst Centre highlighted Bloomlife in June 2026 as an active spinout.
What critics are saying
- Remote prenatal RPM depends on insurer reimbursement; policy changes hit revenue by 2027.
- Bloomlife still markets an investigational uterine-activity and full NST indication.
- If payers refuse reimbursement, Bloomlife's provider model dies.
What makes Bloomlife unique
- Bloomlife's FDA-cleared MFM-Pro monitors maternal and fetal heart rates at home.
- The company integrates EMR workflows, reimbursement, and 19 insurers plus Medicaid.
- PeriGen's April 2026 partnership adds AI analytics for high-risk pregnancies.
Help us improve and share your feedback! Did you find this helpful?